Medpace Holdings (XTER:01P) Cyclically Adjusted PB Ratio: (As of Aug. 29, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

XTER:01P Medpace Holdings Inc XTER:01P
96 GF Score
Price €524.00
GF Value €462.90
Valuation Modestly Overvalued
! 2 Warning Signs
View Full Analysis

What is Medpace Holdings Cyclically Adjusted PB Ratio?

Note: If the price history is too short, we do not calculate current Cyclically Adjusted PB Ratio for this stock. All the historical data is shown as the company's primary share's data instead.

Shiller PE for Stocks: The True Measure of Stock Valuation


Medpace Holdings  (XTER:01P) Cyclically Adjusted PB Ratio Explanation

Compared with the regular PB Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PB Ratio smoothed out the fluctuations of book value during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PB Ratio should give similar results to regular PB Ratio.


Medpace Holdings Cyclically Adjusted PB Ratio Related Terms


Medpace Holdings Cyclically Adjusted PB Ratio Historical Data

* Premium members only.

The historical data trend for Medpace Holdings's Cyclically Adjusted PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Medpace Holdings Cyclically Adjusted PB Ratio Chart

Medpace Holdings Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted PB Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 16.10 27.32

Medpace Holdings Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Cyclically Adjusted PB Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 15.18 25.01 27.32 22.75 24.78

XTER:01P vs : Cyclically Adjusted PB Ratio Comparison

For the Diagnostics & Research subindustry, Medpace Holdings's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Medpace Holdings Cyclically Adjusted PB Ratio vs Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Medpace Holdings's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where Medpace Holdings's Cyclically Adjusted PB Ratio falls into.


XTER:01P
96GF Score
Medpace Holdings Inc XTER:01P
Cyclically Adjusted PB Ratio is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Medpace Holdings Cyclically Adjusted PB Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PB Ratio takes the Book Value per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/B calculation. Because it considers this 10-year average, it's often referred to as the CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio.

Medpace Holdings's Cyclically Adjusted Book per Share for the quarter that ended in Jun. 2026 is calculated as:

For example, Medpace Holdings's adjusted Book Value per Share data for the three months ended in Jun. 2026 was:

Adj_Book=Book Value per Share/CPI of Jun. 2026 (Change)*Current CPI (Jun. 2026)
=15.544/333.9520*333.9520
=15.544

Current CPI (Jun. 2026) = 333.9520.

Medpace Holdings Quarterly Data

Book Value per Share CPI Adj_Book
201609 14.995 241.428 20.742
201612 15.019 241.432 20.774
201703 15.266 243.801 20.911
201706 15.301 244.955 20.860
201709 14.711 246.819 19.904
201712 14.197 246.524 19.232
201803 14.394 249.554 19.262
201806 15.194 251.989 20.136
201809 15.775 252.439 20.869
201812 16.534 251.233 21.978
201903 17.406 254.202 22.867
201906 18.333 256.143 23.902
201909 19.216 256.759 24.993
201912 20.138 256.974 26.170
202003 20.229 258.115 26.173
202006 20.845 257.797 27.003
202009 22.139 260.280 28.405
202012 22.685 260.474 29.084
202103 23.908 264.877 30.143
202106 23.783 271.696 29.233
202109 24.989 274.310 30.422
202112 26.465 278.802 31.700
202203 17.979 287.504 20.884
202206 9.141 296.311 10.302
202209 11.251 296.808 12.659
202212 12.427 296.797 13.983
202303 11.340 301.836 12.547
202306 12.795 305.109 14.005
202309 15.348 307.789 16.653
202312 18.176 306.746 19.788
202403 21.675 312.332 23.175
202406 24.631 314.175 26.181
202409 28.359 315.301 30.037
202412 26.951 315.605 28.518
202503 19.896 319.799 20.777
202506 6.136 322.561 6.353
202509 10.425 324.800 10.719
202512 16.181 324.054 16.675
202603 20.949 330.213 21.186
202606 15.544 333.952 15.544

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

Is Medpace Holdings (XTER:01P) Overvalued in 2026?

Based on GuruFocus' analysis, Medpace Holdings stock appears to be overvalued. The current stock price of €524.00 is trading 13.2% above its estimated GF Value™ of €462.90. GuruFocus considers Medpace Holdings to be Modestly Overvalued.

Key valuation signals for XTER:01P:

  • Cyclically Adjusted PB Ratio:
  • GF Value™: €462.90 vs. price of €524.00 (13.2% above fair value)
  • GF Score™: 96/100 with 2 warning signs

No single metric tells the full story. See the XTER:01P stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Medpace Holdings Business Description

Comparable Companies
Address 5375 Medpace Way, Cincinnati, OH, USA, 45227
Medpace is a late-stage contract research organization that provides full-service drug-development and clinical trial services to small and midsize biotechnology, pharmaceutical, and medical device firms. It also offers ancillary services, including bioanalytical laboratory services and imaging capabilities. The company was founded over 30 years ago and has more than 5,400 employees across 40 countries. Medpace is headquartered in Cincinnati, Ohio, and its operations are primarily based in the US, with additional presence in Europe, Asia, South America, Africa, and Australia. Cinven, a global private equity firm, acquired Medpace for $915 million in 2014 and exited its investment in 2018.
96GF Score

Get the complete analysis for XTER:01P

Cyclically Adjusted PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€524.00
Price
€462.90
GF Value